KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Net Cash Flow (2016 - 2025)

Fulgent Genetics' Net Cash Flow history spans 10 years, with the latest figure at -$67.5 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 2342.95% year-over-year to -$67.5 million; the TTM value through Dec 2025 reached -$5.1 million, up 88.0%, while the annual FY2025 figure was -$5.1 million, 88.0% up from the prior year.
  • Net Cash Flow for Q4 2025 was -$67.5 million at Fulgent Genetics, down from $29.7 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $188.2 million in Q1 2022 and bottomed at -$213.7 million in Q2 2022.
  • The 5-year median for Net Cash Flow is $3.8 million (2024), against an average of -$1.8 million.
  • The largest annual shift saw Net Cash Flow surged 2507.33% in 2021 before it plummeted 2342.95% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$50.0 million in 2021, then plummeted by 77.9% to -$89.0 million in 2022, then surged by 114.89% to $13.3 million in 2023, then plummeted by 120.86% to -$2.8 million in 2024, then tumbled by 2342.95% to -$67.5 million in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Net Cash Flow are -$67.5 million (Q4 2025), $29.7 million (Q3 2025), and $20.6 million (Q2 2025).